Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0027627 (metastases)
 103,950 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A report is presented on the organization and goals of consultative outpatient follow-up of patients with irradiated tumors by the radiotherapeutic oncologist in a radiation therapy clinic. Organization involves a close working relationship with the referring physician and routine patient checkups at regular intervals after radiation therapy. The goals of the follow-up program include detection and treatment of irradiation-induced early and late alterations of normal tissue, assessment of therapeutic results, early recognition of recurrences, metastases and/or additional tumors and initiation of therapy of these. For these reasons standardized follow-up examinations are required. These must be adapted to the type of tumor and supplemented with the usually expensive and time-consuming tumor workup only where there is suspicion of tumor progression or if problems of differential diagnosis arise.
 ...
PMID:[The after-care of tumor patients in radiotherapy]. 17 36

Umder study was the survival rate in 73 patients treated routinely with 5-fluoruracil for recurrences and metastases of gastric cancer. The survival of 33 patients, treated with the clinical effect proved to be reliably higher than that in 40 patients in whom no effect was gained (the time of 50% survival was 7.1 and 2.4 months accordingly). The compared groups of patients did not differ reliably in such prognostic factors as the tumor spread to the onset of chemotherapy and duration of the interval since the primary operation till tumor progression. It is concluded that the longer survival in patients treated with the effect is due to 5-fluoruracil administration.
 ...
PMID:[Survival of 5-fluorouracil-treated stomach cancer patients in the far-advanced stages]. 35 2

Clinical observations and autopsy findings indicate that radical surgery for lung cancer is followed in most cases by tumor progression. The first signs of the progression would more frequently develop during two years postoperatively, and these were due to metastases in distal organs (49.6%) and lymph nodes (35.2%), more rarely due to the recurrence (11.2%) or implantation metastases (4.0%). According to atuopsy findings in patients, died in late terms after radical surgery, the signs of lung cancer progression were revealed in 87.9% of cases. Among these surgical therapy rendered no effect on the frequency and localization of metastases as compared with untreated patients.
 ...
PMID:[Results of the surgical treatment of lung cancer]. 48 75

The cytotoxic index was studied in 38 patients with melanoma. The cytotoxic effect would not be observed in tumor progression or in the persistent absence (1.5 years) of the signs of metastasization and recurrences in case of the previously removed tumor. The positive effect of the cytotoxic test in some cases was gained in the presence only of the primary focus or after the latter and metastases being removed, and in the long-term absence of metastases and recurrences in the period to come. In other cases the positive effect was gained during a short period of time before the appearance of metastases or in progressing of the disease. To fully estimate the results of the study the cytotoxic test should be methodically associated with studying of the blocking effect of patient's serum. The blood groups A. B. O compatibility or incompatibility of patient's and donor tumor cells did not influence the results of the cytotoxic test.
 ...
PMID:[Cytotoxic index in melanoma patients]. 59 9

Under examination was the possibility to reveal clinico-immunological features in patients with soft tissue sarcomas prior to and after surgery. Different immune responses were observed in patients with various forms of tumor progression. In case of a favourable course of the process surgery somewhat stimulates the cell immune response and reduces the titre of humoral antibodies. In patients with the tumor progression despite the employed treatment, a gradual fall of high cell immunity indices with a simultaneous increase of the humoral antibodies titre was noted. Wide metastases spread in the terminal phase is manifested by suppression of the immune response.
 ...
PMID:[Immunologic reactions in patients with soft tissue sarcomas after surgical treatment]. 74 97

This study assess the effects of oral BCG, as a single agent, on tumor progression and on cell-mediated immune function in patients with metastatic malignant melanoma. Thirty patients were studied including 22 with measurable metastatic lesions and 8 with no detectable disease, following treatment of metastases by surgery, radiotherapy, or 5-(3, 3-dimethyl-1 -triazeno)-imidazole-4-carboxamide (DTIC; DIC). Oral BCG was given in doses of 120--240 mg, 1--3 times per week for periods ranging from 9 to 80 weeks and to total doses of from 1.2 to 20.1 gm. Patients were assessed by direct measurements of tumor mass, PPD skin test and in vitro blastogenic responses to PPD PHA. Of the 22 patient with measureable disease, 19 showed tumor progression and none showed regression of any lesion. Of the 8 without apparent disease, 5 remained stable and 3 had tumor recurrence. Of the total group of 30 patients, 8 showed some increased sensitivity to skin testing with PPD. Of 19 tested, 3 showed an increased PPD response in vitro, while 3 showed a decreased response. Six of 20 tested showed an increased PHA response in vitro. Oral BCG alone was not effective as an antitumor agent in patients with metastatic malignant melanoma.
 ...
PMID:The use of oral BCG in the treatment or metastatic malignant melanoma. 78 99

Melanoma cells carry membrane-bound antigens that induced both antibody production and cellular immunity. However, these antigens appear not to be tumor-specific, as the activity of human antisera can be absorbed out by fetal antigens. Nonetheless, the phenomenon of spontaneous regression, though mostly affecting only parts of a lesion, indicates that effective attack mechanisms do exist. Simultaneous tumor progression is due to heterogeneity of tumor cells, which vary widely in antigen expression. Cells that are not recognizable sneak through defense mechanisms and produce metastases.
 ...
PMID:[Immunology of malignant melanoma (author's transl)]. 99 70

In vitro lymphocyte function was evaluated in 61 patients with different clinical stages of malignant melanoma. Thirty-one of these patients had localized disease, 13 regional metastases, 10 distant lymph node or skin metastases, and 7 visceral metastases. Following immunization, in vitro lymphocyte reactivity to three antigens (diphtheria toxoid, tetanus toxoid and alpha-hemocyanin of Helix pomatia) was studied in the presence of autologous serum, in addition to lymphocyte reactivity to phytohemagglutinin (PHA). The relationship of these tests with the clinical stage and the subsequent course of the disease in a 6 months' observation period was determined. The patients with visceral metastases (7) had a lowered lymphocyte reactivity to PHA compared with controls and the patients with other stages, while they also had a low reactivity to the test antigens (only significantly lowered compared with patients with localized disease). All these patients showed tumor progression or died from metastatic disease. Between the other stages (54 patients) there was no difference in lymphocyte reactivity to the test antigens or PHA. No correlation between lymphocyte reactivity to PHA and the subsequent course of the disease could be demonstrated in these 54 patients. However, lymphocyte reactivity to the test antigens following immunization showed a definite correlation with the subsequent course. Sixty-four percent (9/14) of patients without any lymphocyte reactivity to the three antigens showed tumor recurrence or progression, against 3% (1/40) of patients with positive lymphocyte reactivity to one, two, or three antigens. A suppressive effect of autologous serum on lymphocyte reactivity could be found only in 1 of 20 patients with a low reactivity to PHA or antigens. It is concluded that defects in lymphocyte function are related to subsequent tumor growth in patients with malignant melanoma.
 ...
PMID:Humoral and cell-mediated immune response in patients with malignant melanoma. I. In vitro lymphocyte reactivity to PHA and antigens following immunization. 117 27

Twenty-eight patients with inoperable or metastatic carcinoma of the lung who failed to respond to conventional chemotherapy and/or radiotherapy were entered in this study. All of them received repeated courses of multiple chemotherapy (cyclophosphamide, 5-fluorouracil, 6-thioguanine, methotrexate, and vincristine) with or without concurrent intravenous heparin anticoagulation. No tumor regression was noted in any of the 14 patients who received the multiple chemotherapy only. On the contrary, tumor progression was seen in all of them, and subsequently 12 died of their disease. The other 14 patients were anticoagulated with heparin, then received the same multiple chemotherapeutics while anticoagulated. Over 50% tumor regression was noted clinically and radiologically, and occasionally demonstrated histologically in 7 of them. Two patients in this group are alive and well for 1 1/2 years. No increase in toxicity or metastases was noted. The 2 patients who had progression of their disease while on the multiple chemotherapy program alone showed tumor regression when they received the same chemotherapy after heparinization.
 ...
PMID:Heparin and chemotherapy in the management of inoperable lung carcinoma. 120 41

The successful growth of metastatic tumor cells is due to their responses to local paracrine growth factors and inhibitors and their production and responses to autocrine growth factors. At early stages of metastatic progression, there is a tendency for many common malignancies to metastasize and grow preferentially at particular sites, suggesting that paracrine growth mechanisms may dominate the growth signals affecting metastatic cells. At later stages of metastatic progression, where widespread dissemination to various tissues and organs occurs, autocrine growth mechanisms may dominate the growth signals affecting metastatic cells. The progression of malignant cells to completely autonomous (acrine) states can ultimately occur, and at this stage of metastatic progression cell growth can be completely independent of growth factors or inhibitors. Various strategies have been developed to treat cancer that are based on the responses of malignant cells to growth factor or inhibitor analogs, anti-receptor antibodies, or antibody- or growth factor-toxin conjugates. Since the responses and expression of growth factor receptors can change during malignant progression, the development of cancer treatments using analogs of specific growth inhibitors or antagonists of growth factors, such as monoclonal antibodies or other agents, to block growth signaling mechanisms may only be useful at the early stages of malignant cancer progression before widespread metastasis of acrine cells occurs.
 ...
PMID:Paracrine/autocrine growth mechanisms in tumor metastasis. 129 54


1 2 3 4 5 6 7 8 9 10 Next >>